REGENXBIO (RGNX)
(Delayed Data from NSDQ)
$7.85 USD
-0.05 (-0.63%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $7.85 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
RGNX 7.85 -0.05(-0.63%)
Will RGNX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for RGNX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RGNX
Regenxbio (RGNX) Reports Q2 Loss, Lags Revenue Estimates
Aligos Therapeutics, Inc. (ALGS) Reports Q2 Loss, Misses Revenue Estimates
RGNX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Regenxbio (RGNX) Q1 Earnings and Revenues Lag Estimates
Regenxbio (RGNX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Exact Sciences (EXAS) Reports Q1 Loss, Tops Revenue Estimates
Other News for RGNX
Barclays Lowers Price Target for Regenxbio (RGNX) to $37.00 | RGNX Stock News
Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026
REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript
RGNX: Chardan Capital Maintains Buy Rating with $52 Target | RGNX Stock News
Regenxbio price target lowered by $4 at RBC Capital, here's why